News | October 16, 2024
Akums Drugs enters into license and distribution agreement with Triple Hair, Canada
Akums Drugs will undertake this development and commercialization in India
Akums Drugs will undertake this development and commercialization in India
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
CSPC will receive an upfront payment of $100 million from AstraZeneca
The acquisition will strengthen the overall company’s position as leading global CRO services partner
USFDA completes PAI of Lupin’s biotech facility in Pune
Subscribe To Our Newsletter & Stay Updated
